Hereditary breast cancer
review and current approach
Keywords:
breast cancer, genetic testing, heredity, mutation, genetic predispositionAbstract
Hereditary breast cancer is a complex and important condition, representing about 10% of all breast cancer cases. Identifying highrisk patients and possible carriers of pathogenic genetic variants with indication for genetic testing is an essential step to care for these patients and their families. Treatment can be influenced, both surgical and adjuvant, by the existence of mutation, providing the possibility of better results and preventive measures. In Brazil, access to oncogeneticists and genetic counseling is limited. Mastologists and their teams must be trained to identify and conduct the approach of these patients, with the objective of offering an adequate and preventive care, as well as early diagnostics. In the present study, a literature review of hereditary breast cancer aspects, diagnostic, and implications, in patients with and without breast cancer, was performed, aiming to assist in the proper management offered by mastologists, considering general and Brazilian characteristics.
Downloads
References
Brasil. Ministério da Saúde. DATASUS. Estatísticas vitais [Internet]. Brasília: Ministério da Saúde; 2020 [accessed on May 1, 2020]. Available at: https://www.inca.gov.br/numerosde-cancer
Levine EG, King RA, Bloomfiel CD. The role of heredity in cancer. J Clin Oncol. 1989;7(4):527-40. https://doi.org/10.1200/jco.1989.7.4.527
Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11(2):103-5. https://doi.org/10.1016/j.ccr.2007.01.010
Kenney MG, Couch FJ, Visscher DW, Lindor NM. Non-BRCA familial breast cancer: review of reported pathology and molecular findings. Pathology. 2017;49(4):363-70. https://doi.org/10.1016/j.pathol.2017.03.002
Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8(1):319. https://doi.org/10.1038/s41467-017-00388-9
National Cancer Institute. Portal [Internet]. NCI; 2019 [accessed on May 1st, 2020]. Available at: http://www.cancer.gov
Constantino JP, Gail MP, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541-8. https://doi.org/10.1093/jnci/91.18.1541
Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Hered Cancer Clin Pract. 2012;10(Suppl. 2):A29. https://doi.org/10.1186/1897-4287-10-S2-A29
Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles A, et al. Predicting the likelihood of carrying a BRCA 1 or BRCA 2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-31. https://doi.org/10.1136/jmg.2007.056556
Parmigiani G, Chen S, Iversen ES, Friebel TM, Finkelstein DM, Ziogas A, et al. Validity of models for predicting BRCA 1 and BRCA 2 mutations. Ann Intern Med. 2007;147(7):441-50. https://doi.org/10.7326/0003-4819-147-7-200710020-00002
Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025-31. https://doi.org/10.1245/s10434-019-07549-8
Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of Hereditary Breast Cancer: are genetic testing guidelines a tool or na obstacle? J Clin Oncol. 2019;37(6):453-60. https://doi.org/10.1200/jco.18.01631
Thomas E, Mohammed S. Advances in Genetic Testing for Hereditary Cancer Syndromes. In: Pitchert G, Jacobs C (eds.). Rare Hereditary Cancers. Cham: Springer; 2016. p. 1-16. https://doi.org/10.1007/978-3-319-29998-3_1
Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Mason BA, et al. The relative contribution of point mutations and genomic rearrangements in BRCA 1 and BRCA 2 in highrisk breast cancer families. Cancer Res. 2008;68(17):7006-14. https://dx.doi.org/10.1158%2F0008-5472.CAN-08-0599
Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(44):18032-7. https://doi.org/10.1073/pnas.111505210810
Kurian A, Hughes E, Hanford EA, Gutin A, Allen B, Hartman A-R, et al. Breast and ovarian cancer penetrance estimated derived from germline multiple-gene sequencing results in women. JCO Precis. 2017;1:1-12. https://doi.org/10.1200/PO.16.00066
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA 1, BRCA 2, CHEK 2, and TP53 in families at hight risk of breast cancer. JAMA. 2006;295(12):1379-88. https://doi.org/10.1001/jama.295.12.1379
Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol. 2010;4(3):174-91. https://doi.org/10.1016/j.molonc.2010.04.011
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250(4988):1684-89. https://doi.org/10.1126/science.2270482
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-16. https://doi.org/10.1001/jama.2017.7112
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-89. https://doi.org/10.1086/301749
van der Groep P, Bouter A, van der Zanden R, Menko FH, Buerger H, Verheijen RH, et al. Re: germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004;96(9):712-3; author reply 714. https://doi.org/10.1093/jnci/djh114
van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol. 2011;34(2):71-88. https://dx.doi.org/10.1007%2Fs13402-011-0010-3
Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig H, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: The EVA trial. J Clin Oncol. 2010;28(9):1450-7. https://doi.org/10.1200/jco.2009.23.0839
Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MKM, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33(10):1128-35. https://doi.org/10.1200/jco.2014.56.8626
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89. https://doi.org/10.3322/canjclin.57.2.75
Cuzick J, Sestak I, Bonanni B, Constantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827-34. https://doi.org/10.1016/s0140-6736(13)60140-3
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-6. https://doi.org/10.1001/jama.286.18.2251
Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091-99. https://dx.doi.org/10.1200%2FJCO.2012.47.8313
Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660-9. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg.
Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AIM, Collée M, Heijboer HEJ, et al. Survival after bilateral riskreducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723-33. https://doi.org/10.1007/s10549-019-05345-2
Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17(10):2702-9. https://doi.org/10.1245/s10434-010-1136-7
Finch APM, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol. 2014;32(15):1547-53. https://dx.doi.org/10.1200%2FJCO.2013.53.2820
Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059-65. https://doi.org/10.1001/jamaoncol.2018.0211
Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38(18):2080-106. https://doi.org/10.1200/jco.20.00299
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snider C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis. BMJ. 2014;348:g226. https://doi.org/10.1136/bmj.g226
van den Broek AJ, Schmidt MK, van’t Veer LJ, Oldenburg HAS, Rutgers EJ, Russell NS, et al. Prognostic impact of breastconserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg. 2019;270(2):364-72. https://doi.org/10.1097/sla.0000000000002804
Park H, Choi DH, Noh JM, Huh SJ, Park W, Nam SJ, et al. Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations. Int J Radiat Biol. 2014;90(1):90-4. https://doi.org/10.3109/09553002.2013.835504
Pierce LJ, Strawderman M, Narod SA, Oliviotto AE, Eisen A, Dawson L, et al. Effect of radiotherapy after breast conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18(19):3360-9. https://doi.org/10.1200/jco.2000.18.19.336011
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-33. https://doi.org/10.1056/nejmoa1706450
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-63. https://doi.org/10.1056/nejmoa1802905
Achatz MI, Caleffi M, Guindalini R, Marques RM, Rodrigues AN, Prolla PA. Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Glob Oncol. 2020;6:439-52. https://doi.org/10.1200/jgo.19.00170
Chompret A, Brugieres L, Ronsin M, Gardes M, Freichey FD, Abel A, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82(12):1932-37. https://dx.doi.org/10.1054%2Fbjoc.2000.1167
Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-9. https://doi.org/10.1002/humu.20495
Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643-50.
Achatz MIW, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007;245(1-2):96-102. https://doi.org/10.1016/j.canlet.2005.12.039
Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96(4):238-42. https://doi.org/10.1002/ijc.1021
Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw. 2012;10(8):939-42. https://doi.org/10.6004/jnccn.2012.0097
Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MLC, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017;23(11):e38-e45. https://doi.org/10.1158/1078-0432.ccr-17-0408
Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, et al. A Clinical Scoring System for Selection of Patients for PTEN Mutation Testing Is Proposed on the Basis of a Prospective Study of 3042 Probands. Am J Hum Genet. 2011;88(1):42-56. https://dx.doi.org/10.1016%2Fj.ajhg.2010.11.013
Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7(1):35-45. https://doi.org/10.1038/nrc2037
Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251(5000):1451-5.
https://doi.org/10.1126/science.2006419
Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348-53. https://doi.org/10.1053/gast.2001.29611
Figueiredo J, Melo S, Carneiro P, Moreira AM, Fernandes MS, Ribeiro AS, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet. 2019;56(4):199-208. https://doi.org/10.1136/jmedgenet-2018-105807
National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian [Internet].
National Comprehensive Cancer Network; 2020 [accessed on May 27, 2020]. Available at: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer: implications of genetic testing for screening and
prophylactic surgery. Cancer. 2008;113(7 Suppl.):1850-6. Hereditary diffuse gastric cancer: implications of genetic
testing for screening and prophylactic surgery. Cancer.
Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, et al. Frequency and spectrum of cancers in the Peutz–Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209-15. https://doi.org/10.1158/1078-0432.ccr-06-0083
Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol. 2006;4(4):408-15. https://doi.org/10.1016/j.cgh.2005.11.005
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing
and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-62. https://dx.doi.org/10.1038%2Fajg.2014.435
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-9. https://dx.doi.org/10.1093%2Fannonc%2Fmdv022
Wendt C, Margolin S. Identifying breast cancer susceptibility genes – a review of the genetic bachground in familial breast cancer. Acta Oncol. 2019;58(2):135-46. https://doi.org/10.1080/0284186x.2018.1529428
Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med.
;371(17):1651-2. https://doi.org/10.1056/nejmc1410673
Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing
and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243-57. https://doi.org/10.1056/NEJMsr1501341
Yurgelun MB, Hiller E, Garber JE. Population-wide screening for germline BRCA1 and BRCA2 mutations: Too much of a good thing? J Clin Oncol. 2015;33(28):3092-5. https://doi.org/10.1200/jco.2015.60.8596
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Cássio Furtini Haddad
This work is licensed under a Creative Commons Attribution 4.0 International License.
